Cite
HARVARD Citation
Thein, K. et al. (n.d.). 1761PRisk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance. Annals of oncology. p. . [Online].